Investigating aggressive breast cancer in women of African descent
Official title: Project 1
Funded at Beckman Research Institute/city of Hope · NIH-10933462 · Data updated 2026-11-12
This study is looking into how certain aggressive breast cancers, especially in women of African descent, grow and resist treatment, with the goal of finding new ways to improve therapies by focusing on a specific protein called MYC.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $138,774 |
| NIH project number | 5U54CA285116-02 |
| Project ID | NIH-10933462 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women of African descent diagnosed with luminal B breast cancer who are experiencing aggressive disease characteristics.
✕Less likely to help
Patients with other types of breast cancer or those not of African descent may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms behind aggressive luminal B breast cancers, particularly in women of African descent. It aims to identify specific acetylation sites on the MYC protein that contribute to cancer progression and resistance to therapies. By dissecting the molecular pathways involved, the study seeks to uncover new targets for drug development that could improve treatment outcomes for affected patients. The research will utilize advanced techniques to analyze cancer cell behavior and the role of MYC in tumor biology.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival rates for women with aggressive breast cancer.
How similar studies have gone: Previous research has shown promise in targeting specific molecular pathways in cancer, but this approach focusing on MYC acetylation is relatively novel.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Jones, Veronica Christine — Beckman Research Institute/city of Hope
- Study coordinator: Jones, Veronica Christine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.